Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas

Y Shi, M Zou, NR Farid and ST Al-Sedairy

Molecular Endocrinology Laboratory, Department of Biological and Medical Research, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.

Summary. Eukaryotic cell cycle progression is controlled by a host of cyclin/cyclin-dependent kinases (Cdks), that are themselves regulated by multiple factors, including a group of small cyclin-Cdk inhibitor proteins (p15, p16, p21 and p27). The involvement of Cdk inhibitors in carcinogenesis has been demonstrated by the studies of p16. p53 is frequently mutated in thyroid carcinomas and p21/Waf1 is a downstream effector of p53. It is conceivable that genetic defects of genes downstream in the p53 pathway could also be oncogenic. We, therefore, examined a series of 57 thyroid tumours (eight follicular adenomas and 49 carcinomas) for deletion and point mutation of the p21/Waf1 gene. Three different kinds of deletions ranging from 349 to 450 bp were detected in five papillary carcinoma specimens by reverse transcription–polymerase chain reaction (RT–PCR). All the deletions were involved in the second exon of the p21/Waf1 gene. RT–PCR single strand conformational polymorphism (SSCP) analysis of remaining samples failed to reveal any point mutations in the coding region of the gene, except for a polymorphism at codon 31 (Ser to Arg). Genomic Southern blot analysis did not demonstrate any gene deletion or rearrangement in these samples, indicating abnormal RNA splicing may be involved. Analysis of intron–exon boundary and the coding region of the second exon did not reveal any mutation except for a point mutation (C to G) located 16 bp downstream from the splice donor site of the second intron in three out of five samples with p21/Waf1 deletions. Whether the mutation plays any role in aberrant RNA splicing remains to be determined. Among the five samples with p21/Waf1 gene deletions, none of them simultaneously carried a p53 or retinoblastoma (Rb) gene mutation. No p21/Waf1 abnormality was found in the benign adenomas. Thus, 12.5% (5/40) of thyroid papillary carcinoma specimens harboured p21/Waf1 gene deletions. Our data suggest that p21/Waf1 gene deletion is involved in thyroid carcinogenesis and may play an important role in thyroid cell transformation.

Keywords: p21; Waf1; CIP1; gene deletion; RNA splicing; thyroid neoplasm

Progression of eukaryotic cells through the cell cycle is regulated by a family of serine/threonine kinases, the cyclin-dependent kinases (Cdks), whose catalytic activity is modulated by association with different cyclins, which function as regulatory subunits (Norbury and Nurse, 1992; Hunter and Pines, 1994). Sequential formation, activation and subsequent inactivation of a series of the cyclin–Cdk complexes is believed to be essential for orderly transitions through the cell cycle. A family of small cyclin–Cdk inhibitor proteins (p15, p16, p21 and p27) have recently been identified, which bind and inactivate different kinds of Cdks, thus participating in the negative regulation of the cell cycle progression. p16 and p15 inhibit only Cdk4 and Cdk6 among the known Cdks, whereas p21, also known as Waf1 (El-Deiry et al., 1993) and CIP1 (Harper et al., 1993) and p27 can inhibit multiple Cdks, including Cdk2, Cdk4 and Cdk5 (Xiong et al., 1993; Zhang et al., 1993).

The involvement of Cdk inhibitors in carcinogenesis has been demonstrated by the studies of p16. It has been found that p16 was frequently deleted or mutated in a wide variety of human cancer cell lines, as well as in several specific types of primary tumours (Kamb et al., 1994; Schmidt et al., 1994; Mori et al., 1994; Jen et al., 1994), indicating that p16 functions as a tumour suppressor. Although p21/Waf1 inhibits growth of human tumour cell lines when introduced by transfection (El-Deiry et al., 1993), there is only limited information that the p21/Waf1 gene is mutated or deleted in human tumours (Bhatia et al., 1995).

The p21/Waf1 gene is located at 6p21.2 and encodes a protein of 164 amino acids (El-Deiry et al., 1993). Its transcription can be activated by the tumour-suppressor p53, thus providing a critical link between the tumour-suppressing activity of p53 and the cell cycle control. We have previously found p53 mutations (Zou et al., 1993a; Farid et al., 1994) in 24% and retinoblastoma (Rb) mutations or deletions (Zou et al., 1994) in 55% of 49 thyroid carcinoma specimens. The present study was undertaken to find out whether p21/Waf1 is involved in thyroid carcinogenesis and the extent to which abnormalities of p21/Waf1 correlate with those of p53 and Rb.

Materials and methods

All tumour specimens were obtained at surgery and were immediately frozen in liquid nitrogen and stored at −70°C until processed. The clinical staging of thyroid tumours was based on the TNM classification introduced in 1987 by the International Union Against Cancer (Hermanek and Sobin, 1987). Fifty-seven thyroid tumours were studied: eight benign adenomas, 40 papillary, four follicular and five anaplastic carcinomas.

Full-length human p21/Waf1 cDNA probe was obtained by reverse transcription–polymerase chain reaction (RT–PCR) using two flanking primers (see below). The primers were based on the published p21/Waf1 cDNA sequence (Xiong et al., 1993). The resulting PCR product was verified by DNA sequencing following subcloning into a TA cloning vector (Invitrogen Co., San Diego, CA, USA).

RT–PCR and SSCP procedure

Total RNA was extracted by the guanidinium thiocyanate–phenol–chloroform method as described previously (Zou et al., 1993a). Total RNA (5 µg) was reverse transcribed into cDNA in a 15 µl volume, using Pharmacia's first-strand cDNA synthesis kit. The cDNA was then amplified by PCR.
in 25 cycles using two primers (5'-ATTTCGCCAGGAGCCACCTGAC-3', 5'-TCTCCAGACTGAGGGCTTC-3') flanking the coding sequence of the p21/Waf1 gene. Samples were first denatured at 94°C for 2 min and then submitted to 25 cycles of amplification as follows: 30 s denaturation at 94°C, 30 s annealing at 54°C and 30 s extension at 72°C. For SSCP procedure, the PCR products were reamplified in a 25 μl volume using two [−32P]ATP labelled internal primers together with the flanking primers to generate two overlapping fragments, each about 300 bp long, to facilitate SSCP analysis. The two internal primer sequences are as follows: 5'-TGCCCAAGCTCTACCTTCCCA-3' and 5'-TCTCCCAATCTAATCCGCTC-3'. The SSCP analysis was done as described previously (Orita et al., 1989a, b). Briefly, 1 μl of each amplified product was diluted in 20 μl loading buffer containing 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol, and heated at 95°C for 3 min. An aliquot of 2 μl was loaded into 5% non-denaturing polyacrylamide gel with 5–10% glycerol and electrophoresed at room temperature at 30 W for 4–7 h. The gel was then exposed to Kodak XAR-5 film overnight at −70°C.

The PCR amplification of the second exon of the p21/Waf1 gene was performed using the following two primers (Shiohara et al., 1994; 5'-CCTAGTGTTCAATCTCTCCGCGT-3', 5'-AGCCCTTGCATGACATGTCTG-3'). DNA (200 ng) was used for PCR. The samples were first denatured at 94°C for 2 min and then submitted to 30 cycles of amplification as follows: 40 s denaturation at 94°C, 40 s annealing at 55°C and 40 s extension at 72°C.

Sequence analysis
DNA sequencing was performed by the dideoxy chain termination method after cloning the PCR products into a TA cloning vector.

DNA extraction and Southern blot hybridisation
Genomic DNA from tumour samples was extracted as previously described (Sambrook et al., 1989). Southern blot analysis was performed by digesting 10 μg DNA with EcoRI, fractionated on 1% agarose gel and blotted onto a nylon membrane (Hybond-N, Amersham) by capillary transfer. The DNA on the filter was then sequentially hybridised with probes for p21/Waf1 and human thyrotropin receptor. Probe labelling and hybridisation were performed as described previously (Zou et al., 1995).

Results
The coding region of p21/Waf1 cDNA was examined for deletion and/or point mutation by RT-PCR and SSCP in 57 thyroid tumour specimens (eight benign adenomas, 49 carcinomas). The RT-PCR products were analysed on 1.8% agarose gel following ethidium bromide staining. Smaller than the expected 561 bp fragments were observed in five papillary carcinoma specimens (Figure 1), ranging from 100 to 220 bp. Normal-sized fragments were also present in two of the five samples. Southern blot analysis of the RT-PCR products could, however, detect normal-sized fragments as well as the small fragments in all five samples (data not shown). These small fragments could not be amplified from eight benign adenomas or peripheral lymphocytes from ten individuals without known history of thyroid tumours. They were subsequently subcloned and sequenced. As shown in Figures 2 and 3, three kinds of deletions were found, namely mutants A, B and C. In mutant A, the deletion was from nucleotide (nt) −5 (nt 1 was named from translation initiation codon ATG) to nt 445, resulting in a 450 bp deletion in one stage 3 papillary carcinoma sample. This deletion completely blocks the protein synthesis, as there is no alternative translation initiation codon ATG in the remaining sequence. In mutant B, 388 bp coding sequences were deleted (nt 45–432) in three papillary carcinoma samples, two with stage 3 and one with stage 2 disease. In mutant C, 349 bp were deleted (nt 93–441) in one stage 2 papillary carcinoma sample. Both mutant B and C deletions caused a frame-shift and created a stop codon 8 bp and 29 bp downstream from the deletion point, respectively, resulting in a truncated protein.

The remaining samples were analysed by SSCP for the presence of point mutations. Significant electrophoretic mobility shift was detected in six specimens. Sequence analysis revealed a single nucleotide substitution at codon 31 (AGC to AGA), changing Ser to Arg (Figure 5) in all of them. This substitution was reported to be a polymorphism (Chedid et al., 1994; Batlia et al., 1995).

In order to find out whether p21/Waf1 deletions were also present in the genomic DNA of those samples, Southern blot analysis was performed. As shown in Figure 4, no apparent gene deletion, rearrangement or amplification was present, indicating that abnormal RNA splicing may be involved in the deletion of the p21/Waf1 gene.

Given that all the deletions are located within the second exon of the p21/Waf1 gene (Figure 5), we next amplified by PCR the second exon from tumour genomic DNA and examined the intron–exon boundary and the coding region to see if there are any mutations which may lead to aberrant RNA splicing. The PCR products were cloned into a TA vector and a minimum of five clones from each sample were sequenced. As shown in Figure 5, the entire second exon was skipped in mutant A and partial second exon was spliced out, probably by using potential cryptic splice sites: 5'-CA....AG-3' in mutant B and 5'-AC....TG-3' in mutant C, respectively, although no mutations were found at splice sites surrounding the second exon or within the exon. However, one point mutation (C to G) was found in the second intron 16 bp from 5' splice site. This mutation was present in samples with
p21/Waf1 deletions in thyroid cancer
Y Shi et al

Figure 2 DNA sequence autoradiographs showing p21/Waf1 deletion in thyroid carcinomas. Three different deletions were identified: mutants a, b and c. The deletion point is marked by an arrow. Sequencing reactions were performed using single cDNA clone as a template.

Figure 3 Schematic representation of p21/Waf1 cDNA deletion in thyroid carcinoma. The wild-type (WT) p21/Waf1 cDNA is shown at the top, and three different kinds of deletion mutants are shown below. The hatched bar and line represent the coding and untranslated regions respectively. The dark bars represent the flanking primers used to amplify the full-length p21/Waf1 cDNA.

mutant A and C deletions as well as in one of three mutant B deletion samples. It was not present in three normal samples, but was found in one thyroid cancer sample without p21/Waf1 deletion. Therefore, the mutation may be a polymorphism and whether it contributes to the aberrant RNA splicing remains to be determined. It is worth noting that the 5′ splice point of mutant C happens to be in the third nucleotide of the polymorphic codon 31 (AGC/A), and the third nucleotide is adenine instead of cytosine (Figure 3). Adenine would thus serve as a 5′ splice donor site of mutant C. However, we do not know whether this is a chance event or plays any role in abnormal RNA splicing. Two separate PCRs from original tumour specimens were performed to rule out the possibility of enzymatic errors in PCR amplification with Taq polymerase. The results were identical in the separate experiments.

Ten per cent (5/49) of thyroid carcinomas (12.5% of papillary thyroid carcinomas) in this series harboured p21/Waf1 deletions. Among the five p21/Waf1 deletion samples, none of them was found to have either a p53 (Zou et al., 1993) or Rb mutation (Zou et al., 1994). Thus, p21/Waf1 appears to be deleted only in those samples without p53 or
p21/Waf1 deletions in thyroid cancer

Y Shi et al

Table 1 Genetic defects of p53, Rb and p21 in thyroid tumours

| Tumour            | Rb gene mutation (positive/tested) | p53 gene mutation (positive/tested) | p21 gene deletion (positive/tested) | Both p53 and Rb gene mutation (positive/tested) | Both p21 and p53 or Rb gene mutation (positive/tested) |
|-------------------|-----------------------------------|-------------------------------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------------|
| Adenoma           | 0/8                               | 0/8                                 | 0/8                                 | 1/4                                           | 0/4                                                 |
| Follicular carcinoma | 2/4                                | 1/4                                 | 0/4                                 | 5/4                                           | 4/4                                                 |
| Papillary carcinoma | 22/40                             | 10/40                               | 5/40                                | 4/4                                           | 0/4                                                 |
| Anaplastic carcinoma | 3/5                               | 1/5                                 | 0/5                                 | 1/5                                           | 0/5                                                 |

*Zou et al. (1994). **Zou et al. (1993a).
Rb mutations. The information regarding genetic defects of p53, Rb and p21 in this series of tumours is summarised in Table I.

Discussion

We have examined the entire coding region of p21/Waf1 cDNA for deletions and/or point mutations by RT-PCR and SSCP in 57 thyroid tumour specimens (eight benign adenomas and 49 carcinomas, including 40 papillary carcinomas). Subtle p21/Waf1 deletions have been found in five papillary carcinoma specimens. The deletions are involved in the most evolutionarily conserved region (nt 63–180 and nt 390–492) (Huppi et al., 1994), and the truncated p21/Waf1 proteins are probably not functional. El-Deiry et al. (1993) previously reported that introduction into human tumour cells of a mutant p21/Waf1 with a stop codon at nt 222 did not result in significant growth suppression, thus experimentally confirming that the region beyond nt 222 is required for p21/Waf1 function. More defined p21 binding domains involved in the inhibition of Cdk2 and PCNA have recently been identified (Chen et al., 1995; Goubin and Ducommun, 1995). The Cdk2 binding domain was located in the N-terminal part of the protein, between residues 45 and 60 (nt 135–180). A proliferating cell nuclear antigen (PCNA) binding region was mapped to the C-terminus of the protein between residues 142 and 163 (nt 426–489). Cdk2 is required in the G1-S transition and is found in association with G1 cyclins (D1, D3 and E) implicated in the control of passage through the restriction point of cell cycle (Xiong et al., 1992; Koff et al., 1992; Dulic et al., 1992; Pagano et al., 1993).

PCNA is the auxiliary protein of DNA polymerase delta (Bravo et al., 1987) and is thought to be involved in DNA replication and repair processes (Prelitch et al., 1987; Shiviji et al., 1992). p21/Waf1 interacts with and inhibits both Cdk2 and PCNA, thus controlling cell cycle progression and DNA replication (Waga et al., 1994). All three kinds of mutants have lost both Cdk2 and PCNA binding domains. They, therefore, cannot express their inhibitory activity on either Cdk2 or PCNA.

Although normal-sized products were present in the five p21/Waf1 mutant samples, the wild-type allele might be derived from contaminating non-cancerous cells, such as infiltrating inflammatory cells andstromal cells. Another possibility is that both wild-type and mutant p21/Waf1 alleles are present in some of the thyroid cancer specimens. This has been supported by a recent report (Bhatia et al., 1995) that a heterozygous point mutation at codon 63 (Phe to Leu) of p21/Waf1 was found in a Burkitt’s lymphoma cell line. Both wild-type and mutant p21/Waf1 mRNA were expressed in the tumour cell line. Transfection experiments showed that the mutant was less efficient in suppressing clonogenicity than the wild-type. It is, therefore, possible that one wild-type allele of p21/Waf1 may not function sufficiently to cause G1 arrest, thus resulting in uncontrolled cell cycle progression and tumour formation.

Given that gene deletion and rearrangement are not found in the tumour genomic DNA, abnormal RNA splicing is probably the cause of p21/Waf1 deletion. The entire second exon is skipped in mutant A. The common causes for exon skipping include: (1) mutations in the conserved sequence at the 5’ donor site or 3’ acceptor site (Green, 1986; Zielenksi et al., 1995). Most reported cases of exon skipping are due to a single base substitution that changes the universal AG dinucleotide at the 3’ splice site of the intron (Green, 1986; (2) mutations in the exon (Dietz et al., 1993; Matsuo et al., 1991; Wakamatsu et al., 1992). The exonic mutations would either activate a cryptic splice site (Matsuo et al., 1991; Wakamatsu et al., 1992), or interfere with splicing factor binding or RNA secondary structure (Dietz et al., 1993). Although we could not find any mutations in the conserved splicing sequences surrounding the second exon and within the exon, some uncommon events such as mutations in the second intron or beyond the region we have examined may participate in the exon skipping. The potential cryptic S’ splice site (5’-CA...AG-3’) used in mutant B and both splice sites (5’-AG...TG-3’) in mutant C do not follow the 5’GT...AG-3’ rule. The GT–AG rule describes the splicing junctions of eukaryotic nuclear genes and is highly conserved in most, if not all, mammalian cells (Padgett et al., 1986). Utilisation of unconserved cryptic splice sites in mutants B and C may suggest that a single or multiple splicing factor defect may be involved in the abnormal splice site selection, and a partial second exon deletion.

In the present study, we were unable to find any samples having both p21/Waf1 and p53 or Rb mutations. It is known that radiation induces thyroid tumorgenesis, and recent data have shown that radiation-induced G1 arrest in thyroid cells is selectively mediated by the p53–p21/Waf1 pathway (Namba et al., 1995). p53-induced p21/Waf1 participates in the G1/S checkpoint, and inhibits multiple Cdns, including Cdk4, which stimulates cell division by phosphorylation of Rb and release of E2F transcription factor. Loss of p21/Waf1 would probably affect both p53 and Rb tumour-suppressor activities. Thus, p21/Waf1 mutation alone may be sufficient to induce thyroid malignancy.

References

BHAITA K, FAN S, SPANGLER G, WEINTRAUB M, O’CONNOR PM, JUDEDE JG AND MAGRAITH I. (1995). A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt’s lymphoma. Cancer Res., 55, 1431–1435.

BRANO F, FRANK B, BLUNDELL PA AND MACDONALD-BRAVO H. (1987). Cyclin/PCNA is the auxiliary protein of DNA polymerase delta-δ. Nature, 326, 515–517.

CHEDID M, MICHELI P, LENEGEL C, HUPPI K & GIVOL D. (1994). A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene, 9, 3021–3024.

CHEN J, JACKSON PK, KIRSCHNER MW AND DUTTA A. (1995). Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Science, 268, 386–388.

DIETZ H, VALLE D, FRANCOVANO CA, KENDZIOR RJ, PYERITZ RE AND CUTTING GR. (1993). The skipping of constitutive exons in vivo induced by nonsense mutations. Science, 259, 680–683.

DULIC V, LEES E AND REED SR. (1992). Association of human cyclin E with a periodic G1-S phase protein kinase. Science, 257, 1958–1961.

EL-DEIRY WS, TOKINO T, VELCULESCUIVE. LEVY DB, PARSONS R, TRENT JM, LIN D, MERCER WE, KINZLER KW AND VOGELSTEIN B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817–825.

FARID NR, SHI Y AND ZOU MJ. (1994). Molecular basis of thyroid cancer. Endocrinal Rev., 15, 201–232.

GOUBIN F AND DUCOMMUN B. (1995). Identification of binding domains on the p21cipl cyclin-dependent kinase inhibitor. Oncogene, 10, 2281–2287.

GREEN MR. (1986). Pre-mRNA splicing. Annu. Rev. Genet., 20, 671–708.

HARPER JW, ADAMI GR, WEI N, KEYOMARSI K AND EILDEE SG. (1993). The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805–816.

HERMANNEK P AND SOBIN LH. (1987). TM Classification of Malignant Tumors. pp. 33–35, Springer-Verlag: Berlin.

HUNTER T AND PINES J. (1994). Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79, 573–582.
intraexondeletion in the dystrophin complex during T. control. cell human thyroid cells. arrest TAKUMI nuclear Proc. and sensitive detection of in the genesis of many tumortypes. Science, 264, 436-440. cloning, MTSl/CDK4I STEINB. MARKOWITZ Nature, 55, 1689-1694. 4 p21 STEINB. MARKOWITZ (1986). Frequent deletion of p16 and p15 genes in braintumors. J. Clin. Invest., 71, 505-514. XIONG Y, HANNON GI, ZHANG H, CASSO D, KOBAYASHI R AND BEACH D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704. ZHANG H, XIONG Y AND BEACH D. (1993). Proliferating cell nuclear antigen and p21 are components of multiple cell cycle as SV40 DNA replication in vitro. Nature, 326, 471 – 475.